Sign in to view Tara’s full profile
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Tara’s full profile
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
San Francisco Bay Area
Sign in to view Tara’s full profile
Tara can introduce you to 10+ people at Inceptive
Join with email
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
3K followers
500+ connections
Sign in to view Tara’s full profile
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Tara
Tara can introduce you to 10+ people at Inceptive
Join with email
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Tara
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Tara’s full profile
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Activity
3K followers
-
Tara Basu Trivedi shared thisAt Enable Medicine, we allow people to leverage novel spatial biology and single cell technologies without needing to build or buy the infrastructure themselves. We process your samples in the lab, or let you upload data directly to our platform, and give you access to cutting-edge bioinformatics. If you're interested in incorporating spatial information into your pipeline, we'd love to talk to you! Message Sunil Bodapati or me to set up time.
-
Tara Basu Trivedi shared thisSo proud of my mum, Anu Basu, for the work that she does for students and the community at San Jose State University — and thrilled that she was recognized for that work with the university’s Distinguished Service Award!! https://lnkd.in/gU8NrTc
-
Tara Basu Trivedi shared thisBeyond excited to announce that I've joined PACT Pharma, which aims to cure cancer by creating personalized immunotherapies for patients 🧬 Humbled to be part of this team! (Now if only I could figure out how to use Microsoft Outlook effectively...)
-
Tara Basu Trivedi shared thisToday is my last day at Google and X ✨ Seven years ago, I stepped onto the Mountain View campus for the first time as a freshman intern. It was such a fun experience that I came back for 2 more summers before joining as a full-timer in 2016. Since then, I’ve increased productivity in display ads, connected the under-connected to the internet, and contributed to applied machine learning research. Most importantly, I’ve been lucky to meet incredible mentors and friends: thank you for teaching and inspiring me and allowing me to do the same for you. I feel truly blessed to have had this opportunity. It’s with excitement (and apprehension) that I look ahead to the next stage of my career. I know that I’ll carry the lessons learned from the last 7 years with me in my future endeavors!
-
Tara Basu Trivedi reacted on thisTara Basu Trivedi reacted on thisDevOps is complicated. Google Cloud is making it easier with proactive Gemini-based agents that work for you, from design to troubleshooting, cost optimization and much more, leveraging Google Cloud's 50+ MCP servers and 400+ MCP tools. Allowing you to go back to what you want to focus on, your business and changing the world. https://lnkd.in/dVFjh-p5Gemini Cloud Assist at Next ‘26 | Google Cloud BlogGemini Cloud Assist at Next ‘26 | Google Cloud Blog
-
Tara Basu Trivedi reacted on thisTara Basu Trivedi reacted on thisIf you’re fortunate as a VC, you have a handful of moments where you meet a founder and within 15 mins you know you have to invest. I've had one of those moments in 2026, meeting George Kurdin at Monk. Delighted to partner with him, co-founder Joe Zhou, co-investors Acrew Capital (Lauren Kolodny) and Better Tomorrow Ventures (Sheel Mohnot Nihar Bobba), in leading Monk's $25M Series A. At Footwork we have now made several investments focused on transforming the finance stack, which has long been of interest given my partner Mike Smith's role as Stitch Fix CFO both when it was a private and public company. Monk transforms one of the messiest parts of finance: getting paid. For customers like ElevenLabs, Profound, Siro, and Unify, Monk automates the invoice-to-cash lifecycle: invoicing, intelligent collections, cash application, and reporting. The platform typically pays for itself in the first month. The company's vision starts with accounts receivable, but is much bigger. If this resonates, please reach out. More below from myself and Ryan Lawler in Axios.
-
Tara Basu Trivedi reacted on thisTara Basu Trivedi reacted on thisThe hardest problem in enterprise AI is not the model. It is that most of what a company knows lives in the heads of fifteen people, and three of them are about to retire. After nearly six years at Palantir, I am joining Edra as Head of Business and Product Development, fresh off a Series A from Sequoia Capital, 8VC, and A*. I spent those years embedded with people doing difficult work their institutions could not quite see them doing. They carried a map of how the business actually ran: the exceptions, the workarounds, the tacit rules no one had thought to write down. The map was the thing the institution was running on. Every Friday afternoon someone left. The map walked out with them. The next person started from the floor. Edra is building the infrastructure that keeps the map. Not a faster agent. Not a smarter dashboard. A knowledge library that turns what lives in people's heads into something AI agents can read, review, and execute. Eugen Alpeza and Yannis Karamanlakis had been building this from inside the same walls I had been circling for years. When they showed me what they had built, the only surprising thing was that no one had built it sooner. We are hiring in New York and London, across engineering, product, go-to-market, and strategy and operations. More soon. (Hiring link and a smaller room for shorter writing, both in the comments.)
-
Tara Basu Trivedi liked thisTara Basu Trivedi liked thisWe are hiring once again here at Lilly Gene Therapy! We have two exciting roles open for a scientist come and join our growing portfolio of gene therapy assets: 1 - Based here in Boston MA, we are hiring for a CAR-T cellular engineer, focused on genomic integration therapies for CARs. https://lnkd.in/e8WugZnD 2 - We are hiring a leadership role based in Redwood City, to lead AAV discovery efforts! https://lnkd.in/eAWtVVJ6
-
Tara Basu Trivedi liked this#SJSU students! Are you working on a startup idea? Submit your business plan to the Silicon Valley Business Plan Competition by April 26, 2026. You could win $10,000! And you’ll receive feedback from our amazing industry judges. Get going now! Lucas College and Graduate School of Business at SJSU San José State University Meghna Paul Sriram Sridhar Alfonso de la Nuez Subhankar Dhar | John Murray PhD | Gary Richman | Iris Xiaohong Quan | Manie Kohn | RJ Rimando | Reshma ShahSilicon Valley Center for Entrepreneurship @ SJSU
Silicon Valley Center for Entrepreneurship @ SJSU
1wTara Basu Trivedi liked thisDo you have a business idea you’d like to turn into a real startup? The Silicon Valley Business Plan Competition (SVBPC) 2026 is a great opportunity to refine your business concept, get real feedback, and compete for funding. Why apply? 💡 Get mentorship & feedback from experienced entrepreneurs 🚀 Turn your idea into a full business plan 💰 Compete to win $10,000 for your startup 2nd place: $5,000 3rd place: $2,500 🌟 Gain exposure to investors in the Silicon Valley ecosystem 📅 Application Deadline: April 26, 2026 🎤 Final Pitches: May 12, 2026 Eligibility note: At least one member of your team must be a current SJSU student. If you already worked on a project for #SVIC, you’re in a perfect position — this is just building on what you’ve already started. 👉 Apply here: bit.ly/svbpc26 -
Tara Basu Trivedi liked thisTara Basu Trivedi liked thisyou work in b2b saas but i work in b2b sass hun
-
Tara Basu Trivedi reacted on thisTara Basu Trivedi reacted on thisPat Opet wrote a line in his latest JPMorgan post I can't stop thinking about: "The easy path should be the safe path." It's the clearest articulation of the defender's problem I've seen and it maps almost one-to-one onto how Alex Pall and I underwrite our cybersecurity investments at Mantis Venture Capital. Four primitives: code, data, detection, identity. Four portfolio companies (Chainguard, Bedrock Data, Scanner, Kepler) each taking one and going all the way down. Full write-up below, and Thanks to Pat for the spark!
-
Tara Basu Trivedi liked thisTara Basu Trivedi liked thisOur culture here at Athelas Commure is not for everyone. We are upfront about who we are and we work with people hungry for that environment. More on who we are here courtesy of Alfred Lin - our OG from Sequoia Capital. https://lnkd.in/gGXPe9Be Tanay Tandon Dhruv Parthasarathy Hersh Solanki Dan Warner Patrick Winter Andrew Jin Max Krueger Cem Torun Asrin Sevinc Sam Ascher Greg Martinez, PT, DPT Daniel Stewart PT, DPT
Experience & Education
-
Inceptive
******* *** **
-
****** **
***** ** *****
-
****** ********
******** ***********
-
******* ******** ******
****** ** ******** ************** * *** undefined undefined
-
-
******* **** ** ******* ****** ** *********** *** ******* ********
****** ** ******* * ** *********** ********
-
View Tara’s full experience
See their title, tenure and more.
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View Tara’s full profile
-
See who you know in common
-
Get introduced
-
Contact Tara directly
Explore more posts
-
Matt Ocko
DCVC • 13K followers
Billion$ in upfronts and licensing. Why? Real clinical insights at unprecedented speed, accuracy, and cost efficiency. Faster motion to the clinic with fewer disappointments. Real potential patient impact in the near term. DCVC #TechBio companies are helping punch death in the face and preserve human dignity and autonomy in the face of disease.
11
-
Zoey Li
MIT Sloan School of Management • 5K followers
Loved geeking out with some of the sharpest minds in healthcare VC this week. It’s always energizing to hear folks unpack where digital health, AI, and care delivery might be heading — especially because there are thoughtful perspectives across the spectrum. A few takeaways that stood out: 1️⃣Cost containment is top of mind — though strategies vary widely. Everyone agrees rising costs are unsustainable, but the approaches differ: specialty care models, operational efficiency, labor leverage, and infrastructure all play a role. Examples: Heartbeat Health (cardiology), CareBridge (LTSS/HCBS; acquired by Elevance), Diana Health (OB/GYN across high-Medicaid hospitals). 2️⃣AI has real promise — but the bar is very high. There’s no shortage of enthusiasm around AI, but also healthy skepticism about where value will truly accrue. The consistent theme: depth of technical differentiation + measurable workflow impact. Example: Ambience Healthcare — backed for its technical rigor and broader infrastructure vision beyond scribing. 3️⃣The commercial employer market is evolving fast. Especially among small and mid-market employers, we’re seeing more innovation around transparency, dynamic plan design, and benefit flexibility. Examples: Helm Health (dynamic copay), Garner Health (transparent navigation), Lynx (ICHRA infrastructure). 4️⃣Value-based care continues to be a long-term direction for the system. While there are different views on timing and adoption, the shared belief is that models improving efficiency, right-site-of-care, and aligned incentives will play an increasingly important role. Examples: Equip (case-rate eating disorder care — strong outcomes without needing full risk), InStride Health (severe OCD/child behavioral health). 5️⃣Epic remains one of the most influential forces in the market. Even without launching a full product, Epic can “freeze” an entire category simply by announcing that they’re entering it. While their first versions often deliver ~60% of best-in-class functionality, their scale, distribution, and embedded workflows mean adoption can still be high — and the ripple effects for startups are significant. Huge thank you to our panelists — all incredible MIT alums — for sharing such balanced, thoughtful insights: Payal Agrawal Divakaran (.406 Ventures), Annie Weissbach (Echo Health Ventures), Laura Veroneau (Optum Ventures), Ellen Herlacher (LRVHealth), and Andrew Geraghty (Morgan Health). And grateful for my Sloan Healthcare Club teammates Kendall (Kenji) Yoshii and María Soledad Ross — truly the best partners to co-lead this with. Always love being part of this community. Already excited for what’s next. #DigitalHealth #VentureCapital #Startups #EarlyStage #MITSloan
36
2 Comments -
Anant Pai
General Catalyst • 3K followers
Late to share but was so great to host Elad Walach (Aidoc), Tanay Tandon (Commure), and Keisuke Nakagawa, MD (UC San Diego Health) at the General Catalyst SF HQ for a conversation about the next-gen healthcare stack. Here are my key takeaways: 💵 Know Your Customer's Financials: Understanding hospital P&Ls is crucial -- designing product that that aligns directly with specific line items ensures clear ROI for buyers. 💼 Regulatory Tailwinds: The Cures Act is transforming data access. Recent rulings now prohibit EMRs from blocking data scraping, paving the way for faster, more straightforward integrations. 🐴 AI as a Strategic Entry Point: Giving commodity product away at a low price can serve as a wedge into more lucrative categories (e.g., from scribing to RCM). 👩💻 From Point Solutions to Platforms: Hospitals are moving away from fragmented tools to prevent the "swivel chair problem." But most platforms start as point solutions focused on high value problems. Holly Maloney Chris Bischoff Elena Viboch Alexandre Momeni Tania Alvarez #HealthcareInnovation #AIinHealthcare #DigitalHealth #HealthTech #GeneralCatalyst
54
1 Comment -
Julie Castro Abrams
How Women Lead • 33K followers
Clinical trials have historically excluded the patients who need them most. That’s exactly what Dr. Hala Borno and the Trial Library team are making clinical trials a care option for every patient. Through How Women Invest Fund III, we’re proud to join SemperVirens VC, NEXT Ventures, Sanofi Ventures, Lux Capital, Civilization Ventures, Overwater Ventures and others in Trial Library’s $10M Series A. As an investor, I’m looking for companies that realign incentives across an entire system: patients, providers, payers, and biopharma. Trial Library does exactly that, making innovation accessible while reducing healthcare costs for everyone. Thrilled to welcome Hala and the team to the How Women Invest Fund III portfolio. Read more: https://lnkd.in/gEgtGN9p
22
4 Comments -
Deniz Kavi
Tamarind Bio • 13K followers
Today, we announce Tamarind Bio’s $13.6M Series A, led by Dimension, with participation from Y Combinator. Tamarind has now become the trusted platform for molecular AI inference, serving tens of thousands of scientists, including 8 of the top 20 pharma, dozens of biotechs and research organizations. Since last year, we’ve grown revenue 7x and are grateful to work with world-class biopharma R&D organizations like Bayer, Boehringer Ingelheim, and Adimab. — When we started two years ago, a few brave biotechs took a chance with us. Hoping this new company, providing easy access to computational drug discovery tools, would enable their scientists to apply foundation models to real therapeutic applications. Since then, our library of AI models has grown to hundreds, not just open-source tools, but also our users’ internal protocols, proprietary models trained on users’ own data, pipelines of multiple models together and more! Now, we are doubling down on our commitment to building the core AI and data infrastructure to power the next generation of medicines. We will continue to support open models, strengthening them with proprietary data, and prioritize access to all scientists. Join us as we build the infrastructure for all AI-powered drug discovery.
1,286
88 Comments -
Kunal Sarda
Arya • 4K followers
This morning, Axios broke the news that Arya Health has raised an oversubscribed $18.2M Series A. This capital is fuel for accelerating our mission of using AI to bring humanity back to healthcare delivered across homes, communities, and screens. In a world obsessed with AI, we wanted to remind everyone that behind every algorithm, there are still humans - the ones building it, and the ones it’s meant to help. So I asked my 9-year-old daughter Arya - the namesake behind the company - to help me tell the "human story" of why we exist. The story that somewhere along the way, we've made providers really busy with all the "chores" to be done around delivering distributed care. Forms. Portals. Calendars. Clicks. Text Reminders. Desperate phone calls. So busy that they don't have enough time-or resources-for what matters. Connecting deeply with those in need of care. And with those delivering care. We built Arya Health to fix that. Because the most urgent job for AI right now isn’t to become smarter than humans - it’s to make space for more humanity. And for that, it needs the best humans - the builders, dreamers, and doers who believe that technology should make people feel seen, not replaced. If you’re a provider and feel like busywork is keeping you from the humanity in care, please reach out. We'd love to help. If you're a builder and want to build AI with a focus on humanity, please reach out. We need more firepower to move faster. -- Special gratitude to: ✨ Aike Ho (ACME Capital) for leading our Series A round, ✨ Byron Ling (Twelve Below), Alexander Rosen (Ridge Ventures) and many other early backers for doubling down on their conviction in Arya, ✨ Colin M Evans (OpenAI) for seeing and backing our AI-powered vision, ✨ Industry juggernauts Fred Johnson, Chris Gerard, Sandra Bell and Guy Friedman for putting their trust in Arya as customers, ✨Melinda Phillips for trading her home care CEO gloves for Care@Home leader at Arya, ✨My co-founder Arunram K. for being the perfect yin to my yang, ✨Zach Weinberg (Operator Partners) for reminding me that it will take great pain, time and commitment to build the "next Flatiron Health" in NYC, ✨Finn Murphy (Nebular) for reminding me that it's my job to take big bets, ✨Joshua Rahn (Oceans) for reminding me that it's OK to be human, ✨My partner in life Goksu Dogan for reminding me that if this was easy, anyone could do it, ✨And my little Arya for reminding me every day that building a business is never "just business". It's personal. Especially in healthcare.
422
148 Comments -
Nate Loewentheil
Commonweal Ventures • 15K followers
#AmTech Weekly Roundup: Citizen Health raised $30 million in Series A funding from 8VC, Headline, and Transformation Capital. Citizen is building a healthcare advocacy and navigation platform for patients with chronic illnesses. Farid Vij, Nasha Fitter Vulcan Elements raised $65 million in Series A funding from Altimeter and One Investment Management. Vulcan is reshoring production of rare-earth magnets, which are used in everything from drones to semiconductor fabrications to hard drives and automotive vehicles. John Maslin, Piotr Kulik GoodShip raised $25 million in Series B funding from Greenfield Partners, Bessemer Venture Partners, and Ironspring Ventures. Goodship is building an AI-powered freight management platform, analyzing shipping and operations data to reduce transportation costs and lateness. Ryan Soskin, David Tsai #SupplyChain #Healthcare #CriticalMinerals #VC
38
10 Comments -
Léa Jabbour
Lightbank • 2K followers
Thrilled to publish this piece with TMV ! 🚀 Over the summer, I had the chance to dive deep into Clinical AI adoption — speaking with providers, payers, health system leaders, and regulatory experts about both the opportunities and the real challenges ahead. A huge thank you to everyone who shared their time and perspectives with us — your insights made this research possible. And special thanks to Emma Silverman for her guidance and partnership throughout this project. Excited to continue exploring how AI can meaningfully support clinicians, streamline workflows, and ultimately improve care delivery for all. 📖 Read the full report here: https://lnkd.in/eVzd9Cqb
54
3 Comments -
Lucas Buchheim-Jurisson
POM Health Systems • 4K followers
Tarek Mouhieddine M.D. and I are excited to announce that POM Health is coming out of stealth today and opening a limited beta to early customers. We were founded with a simple mission of catching as many cancers as possible as early as possible and upgrading a cancer screening paradigm that too often catches disease late. In the U.S., screening catches just ~14% of cancer cases, and around half of diagnoses are made at Stage III+. Despite having world-class detection technologies, we routinely screen for just 5 out of 200+ cancer types, often at multi-year intervals between screens, and most people won’t interact with an oncologist until there’s already a high suspicion of cancer. The result: 625k+ deaths from cancer annually in the US, 70% of which are in cancers without guideline-recommended screening, and far too many people believe their annual physical is an effective warning system. Elite cancer centers around the world (like where Tarek practices) have made significant advances in cancer detection and interception that have not yet translated to our primary care and insurance-driven screening system. With AI, we can now bring these advances to millions. Through POM Health, we offer access to more comprehensive cancer screening. Screening is led by world class oncologists, powered by AI, and accessible via telehealth, with one-time and annual subscription offerings. POM's cancer screens use multiple detection modalities (including sample-based biomarkers, MCED, imaging, and genetics) to provide broad coverage across 90%+ of cancers, with overlapping coverage for 80%+. When a cancer signal is detected, your POM oncologist drives the next step quickly. The lifetime risk of acquiring cancer stands at 39% in the US and early onset cancers have doubled since 1990. Cancer isn't a rare disease and we believe people should have an option to mitigate their cancer risk. Now serving beta test users in: MA, NY, and FL (CA soon, and waitlist open for all other states) Learn more: https://lnkd.in/e9qcaru9 Questions: lucas@pomhealth.xyz or tarek@pomhealth.xyz (POM = Peace of Mind, which everyone deserves when it comes to cancer) Thanks also to our first investor Leo Korsunsky!
42
8 Comments -
Amit Sharma
Black Jays Ventures • 2K followers
⚡️ We've been sitting on this news for a while. Lotus Health AI was our first investment from Fund II and so aligned with with our mission and investing approach that we simply had to say yes (and I'm so glad we did). 💡 The US spends $5T/yr on healthcare yet 100M Americans don’t have a primary care doctor and our health outcomes trail almost all industrialized nations. Physician supply and affordability are the two main barriers to universal care. Technology is the only way we can expand care access. Lotus Health AI is the first AI doctor, powered by real doctors who review and oversee care. It’s a real medical provider able to diagnose, prescribe, and refer. Built on millions of peer-reviewed studies and major clinical guidelines, it collapses the cost of care, make doctors 10x more productive, and provides world-class primary care for free. 🙏🏽 Honored to be a part of this journey with KJ Dhaliwal and the rest of the incredible team at Lotus Health AI alongside world class investors Mamoon Hamid, Annie Case, Saar Gur, and others. cc: Black Jays Ventures, Jay H. Kim, Brian Muller, Tim Thimmaiah
33
1 Comment -
Kenny Workman
LatchBio • 7K followers
Money is tight in biotech. As NIH grants and venture funding dry up, we are seeing teams reach for publicly available datasets as a replacement or supplement to internal data generation. These teams are building large and tailored atlases: pooling molecular data from hundreds of studies and thousands of patients in the exact disease and tissue areas of interest to internal programs. We see two dominant curation models: 1/ Outsourcing to specialized solution providers (Excelra, Pythia Biosciences, miraomics). More common across our pharma clients who already have procurement processes (and budget) in place. 2/ Building internal labeling teams. Common in upstarts investing in a computational platform, tool development and tight feedback loops with model training. Public data is a powerful and underutilized resource, but the savings in capex come with an enormous human labor cost. These datasets are highly unstructured and their practical use requires purpose built tooling. We have seen adoption of Latch across both curation models: 1/ We equip solution providers with modern infrastructure and curation tools to deliver faster and higher quality results to clients. We provide a portal for them to distribute and reuse their clean data to our customer base for additional revenue. 2/ We train and onboard internal biotech teams to a suite of curation tools that increase ingestion throughput without sacrificing control. While there is a lot of talk about AI/ML transforming R&D, the curation products we're building are the first instance (I've seen) of LLMs having truly outsized economic impact on research. Some concrete tasks: - Constructing count matrices from unstructured author supplements - Harmonizing metadata against controlled vocabularies using entire papers - Using paper information and general immunology knowledge to create first pass ("best effort") cell type annotations You still need a "human in the loop", but we are seeing per-dataset curation times drop from 4/6 hours to 10mins/1hr. High variance but generally OOM improvements. Engineering drives the efficiency and trends in constituent tooling points (eg. swapping in better models) point to further and rapid gains. We are in the design partnership phase with a handful of companies across both groups. Reach out to work with our team in this early phase and otherwise looking forward to an exciting product release late this summer.
114
1 Comment -
Aike Ho
ACME Capital • 5K followers
What drew us to Arya Health wasn’t just the technology, but the clarity of purpose behind it. Kunal and Arunram are solving one of the hardest and least glamorous problems in healthcare: the broken labor operations that keep post-acute care running. This is a $500B+ market, nearly 10% of U.S. healthcare spend, yet most of it still depends on manual coordination. Every day, agencies are juggling thousands of nurses, last-minute shift cancellations, credential expirations, and payroll calculations across dozens of systems. The administrative burden is crushing, and it’s only getting worse as the population ages and demand for home-based care accelerates. Arya has built AI agents that act as a true digital workforce for healthcare operations - autonomously handling scheduling, onboarding, compliance tracking, and payroll. Their scheduling agent alone manages complex variables like patient needs, clinical fit, distance, and bonus pay, continuously rebalancing assignments in real time. The early traction has been remarkable. Customers whom we talked to consistently describe Arya as transformational - “what they’ve always dreamed of” and a product that will “forever change the industry.” Agencies are already seeing utilization rise from roughly 60% to over 80%, driving significant improvements in coverage, patient outcomes, and operating margins. What stands out most about Kunal and Arun is how deeply they care about the people behind these operations. They spend time in the field with schedulers, caregivers, and agency leaders - the unsung heroes who hold the healthcare system together - and they build with empathy and urgency. That care shows up in the product and in every customer relationship. At ACME Capital, we believe the most impactful AI companies will rebuild critical industries from the inside out. Nurses, home health aides, and post-acute caregivers are the backbone of our healthcare system, and often the backbone of their communities. Arya Health is giving them the modern infrastructure they deserve. Congratulations to Kunal, Arun, and the entire Arya team on your oversubscribed $18.2M Series A. We’re proud to lead this round and partner with you as you reimagine how care gets delivered across homes and communities.
23
-
Daniel Dacey
dovetail biopartners • 7K followers
We're reintroducing Dovetail Biopartners as the first integrated data science and ecosystem partner for biology innovators. We’re not a consulting firm. Not a software vendor. Not a dev shop. We’re the technical backbone and strategic partner for teams doing real science with complex data. We're the digital team saving you from the everyday fires that slow you down. 🤖 Dovetail started because I was tired of watching biotech teams generate valuable data without the infrastructure, workflows, or guidance to use it. I had worked in molecular diagnostics, clinical labs, and bioinformatics. The pattern was always the same: scattered tools, no scalable systems, no clear path forward. We began by helping teams build pipelines to get through early experiments. But the needs didn’t stop there. We kept getting pulled into infrastructure, automation, interpretation, and strategy. What started as focused analysis became full-stack support. Today, Dovetail delivers end-to-end solutions, from cloud infrastructure to biological insight to platform development, with a model that scales with your science. We’re also adding something most data groups don’t: ecosystem access. When the time is right, we connect clients to trusted investors, partners, and collaborators. We’ll amplify client progress through a new newsletter and social funnels and host exclusive events. And here’s how our services are structured now: 🐦 Nest Strategic advising for experimental planning, operational design, and milestone readiness. 🐦 Lift Secure AWS infrastructure, data governance, and workflows built for life science environments. 🐦 Glide Automated pipelines, curated analysis, and expert interpretation across omics, imaging, and multi-modal datasets. 🐦 Ascend Platform development, AI and ML deployment, advanced analytics, and custom software built around your science. We don’t take equity. We don’t overbuild. We act as a true partner across science, data, and decision-making. Also, FlockIQ is coming soon. It’s a services-first platform that gives clients real-time access to tools, seamless data management, and expertise in their own secure environment. Built to make our model faster and more connected, not less human. This rebrand is about building the kind of support structure the life sciences community actually needs. Not more noise. Not tools for the sake of tools. Just the right mix of infrastructure, insight, and partnership that helps teams move with clarity and confidence. The environment is shifting. Early-stage funding is tighter. Public support is less reliable. Moving forward will require better coordination, more trust, and new ways of working together. dovetail biopartners is built to meet that moment. If you’re serious about solving real problems, we’re ready to work with you.
56
2 Comments -
Bridget Duru
Rethink Capital Partners • 6K followers
Too many older adults spend more energy navigating the healthcare system than actually receiving care from it. The administrative complexity surrounding healthcare — coordinating between specialists, managing insurance, completing paperwork, accessing resources — has become a barrier in its own right, and for the 60 million Americans over 65, that burden falls hardest on the people least equipped to carry it alone. Understood Care is fixing that. As the first AI-native patient advocacy platform, they connect Medicare patients with dedicated human advocates who help them overcome the upstream barriers that so often stand between a patient and the care they need — scheduling appointments, coordinating providers, completing applications, accessing resources — at no cost to nearly every patient they serve. Behind the scenes, their AI co-pilot Ava handles the heavy lifts that let advocates focus on what matters most: the relationship. At Rethink Education, we invest in companies that expand access to essential services for underserved populations. Understood Care does exactly that. Sam and Kevin have built something technically sophisticated, operationally rigorous, and genuinely mission-driven — and the traction they've built in under a year, now spanning all 50 states and relationships with three of the nation's largest Medicare Advantage plans, speaks for itself. Proud to have co-led their seed round, and even prouder to be a partner as they build toward what comes next. Congratulations to the full Understood Care team on this milestone. 🎉 Sam Wu Kevin Bailey Matt Greenfield Zeal Capital Partners 1984 Ventures Y Combinator Emily Zhen Farzad Soleimani, MD, MBA, FAAEM
49
10 Comments -
Morgan Cheatham, MD
Breyer Capital • 35K followers
There's a new question in every health tech buying cycle that didn't exist 18 months ago: "Is this already on the roadmap of our foundation model vendor?" As we discussed in our 2026 healthcare predictions, we are entering a moment where the end user, clinicians and operators included, can increasingly build software themselves using agentic coding environments. In practice, this shows up when a CIO asks whether a proposed point solution is meaningfully different from what their existing foundation model could deliver with internal prompts, guardrails, and a few weeks of engineering time. This shift is quietly reshaping the competitive calculus. Startups selling into healthcare enterprises no longer compete only with the EHR vendor’s roadmap. They also compete with what a foundation model provider can plausibly ship for that customer, often faster and at lower marginal cost. Importantly, while the moat around building software is eroding, the moat around running software in healthcare is not. Healthcare enterprises are not set up to independently handle deep workflow integration, continuous iteration, reliability at scale, and governance across clinical, legal, and regulatory dimensions. That operational gap is where durable companies are still built. We expect this dynamic to introduce real friction into buying cycles for point solutions with thin moats. At the same time, it expands opportunity for companies with defensible data assets, deep workflow entrenchment, and true platform potential. Artera and Atropos Health are two strong examples from Breyer Capital's portfolio, both highlighted in the article. Special thanks to Brian Gormley for featuring our perspective in today's The Wall Street Journal piece on OpenAI and Anthropic's entry into healthcare. Jim Breyer Daniel Breyer Andre Esteva, PhD Brigham Hyde
281
29 Comments -
Yoga Balaji
Pragmatrix Technology • 2K followers
Having worked with cell therapy organizations for nearly two decades, I've seen the same scenario repeatedly: Leadership teams shocked when calculating the true cost of their manual sample tracking systems. When I visit labs still using spreadsheets for GMP-regulated environments, I don't immediately push for change. Instead, I ask them to track just three metrics for one month: - Hours spent searching for samples - Time dedicated to preparing for FDA audits - Number of data entry corrections made daily The results have consistently astonished them. One mid-sized cell therapy organization discovered they were losing 23+ hours weekly just searching for samples across freezers. Their audit preparation consumed over 120 hours quarterly. Most concerning to me was their sample location error rate: 3.8%. In cell therapy, where patient treatments depend on sample integrity, this margin is simply unacceptable. What many fail to calculate is the hidden compliance cost - the regulatory exposure from inadequate Chain of Custody (COC) and Chain of Identity (COI) documentation. I've witnessed FDA inspectors zero in on these gaps immediately. Through implementing PragLife's Storage Inventory system with features specifically designed for GMP regulations, I've seen organizations transform these metrics: 85% reduction in sample location errors 75% less time spent on inventory audits Near-perfect compliance documentation Beyond metrics, the team's peace of mind during regulatory inspections is perhaps the most valuable benefit - something impossible to achieve with manual systems.
13
-
David H. Crean, Ph.D.
Cardiff Advisory LLC • 32K followers
I was honored to contribute insights to this piece on San Diego's biotech ecosystem—a market I've watched evolve significantly over 27 years in healthcare and life sciences. The article features 11 powerhouse companies, from Illumina and Thermo Fisher to emerging leaders like Element Biosciences and Crinetics. But beyond the profiles, it captures something essential about what makes San Diego different. Three observations from the ground: 1. Density without bureaucracy. The Mesa creates a true innovation corridor—UC San Diego, Salk, Scripps Research, and Sanford Burnham Prebys interweave with startups and scaled biopharma. This proximity reduces friction for diligence, talent recruitment, and specialized services in ways Boston and the Bay Area can't replicate. 2. Science-led, but transaction-optimized. San Diego has evolved from "discovery-first" to a complete company-building engine. Teams now design programs around pivotal endpoints, clean CMC plans, and partner-ready data packages earlier. Good science doesn't just get published here—it gets built. 3. Capital is increasingly earned. We're seeing more structured financing (tranched rounds, milestone-based pay-ins), CVRs, and hybrid collaborations. Strategic partners underwrite risk more explicitly. The winning teams treat capital strategy as a product—staging proof points and designing deal structures that preserve upside while de-risking 12-24 months out. Looking ahead, I expect San Diego's next growth phase to be defined by modality-driven oncology, neuroscience/neurodegeneration, precision immunology, and industrial-strength enabling platforms. The market increasingly rewards companies that combine compelling biology, manufacturability, and a partner-ready clinical narrative. I hope you find the article worth a read, especially if you're tracking West Coast biotech or thinking about where innovation capital flows most efficiently. #Biotech #LifeSciences #SanDiego #Innovation #InvestmentBanking #Dealmaking #Healthcare
96
4 Comments -
Marc Sluijs
10K followers
Lumos Labs (Lumosity) provides a great example of how to do DTx right: first prove that people love the product (100M users paying out of pocket), iterate, refine and demonstrate engagement, generate evidence at scale and only then move towards a regulated environment... many DTx companies seem to forget they are in the first place a consumer mobile tech company that needs to deliver a compelling experience... (another good example would be Pokemon Sleep with $100M revenue in its first year) https://lnkd.in/egqju5TY
38
4 Comments
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content